MOLOGEN AG
MOLOGEN AG: First patient enrolled in TEACH study to treat HIV patients with MGN1703
MOLOGEN AG / Key word(s): Study MOLOGEN AG: First patient enrolled in TEACH study to treat HIV patients with MGN1703 Berlin, June 3, 2015 – The biotechnology company MOLOGEN AG announced today that its partner, the Danish Aarhus University Hospital, treated the first patients in the TEACH study. The collaboration started in early May 2015. Patient enrollment is expected to be completed within the next months. The aim of the so-called TEACH study is to see if the immunotherapy with MGN1703 can activate the innate and adaptive immune system in HIV (Human Immunodeficiency Virus) patients to enhance killing of the HIV infected cells. Aarhus University Hospital will conduct the trial in two hospital centers in Denmark and already received respective funding from the American Foundation for AIDS research (amfAR). MOLOGEN will provide the immunomodulator MGN1703. This is the first time that MGN1703 is evaluated in patients with diseases other than cancer. Thus the potential range of applications of the product could be expanded. MGN1703 is currently being investigated in the registration trial IMPALA in colorectal cancer and in the randomized trial IMPULSE in small cell lung cancer. Both studies are currently enrolling patients. About TEACH The primary endpoint of the study is the change in proportions of activated natural killer cells in the patients. Secondary study endpoints include, among others, a collection of safety, virological, immunological and pharmacodynamic data. HIV infects the immune system and destroys or affects the proper function of immune cells. Without antiretroviral treatment this eventually leads to immune deficiency and the immune system can no longer fight off a wide range of infections and diseases. HIV remains a serious worldwide health issue. According to estimates by WHO and UNAIDS (United Nations Programme on AIDS) 35 million people worldwide were living with HIV at the end of 2013. Some 2.1 million people became newly infected in that same year, and 1.5 million died as a result of HIV-related causes globally. About MGN1703 MOLOGEN AG The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully. For more information on the trials please visit www.clinicaltrials.gov. With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
2015-06-03 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
364871 2015-06-03 |